For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

SWOG S1418

Trial Overview

Official Title

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Study Purpose

To determine if adding pembrolizumab to the standard treatment for triple negative breast cancer, decreases the risk of the cancer returning (after receiving standard chemotherapy and/or radiation).

Diagnosis

Stage II/III Triple Negative Breast Cancer

Eligibility

Patients must have had chemotherapy followed by surgery.

At least 1 cm of residual tumor tissue, or any residual positive lymph nodes, must be remaining at surgery.

Radiation (if applicable) may be done before or during study.

Patients must sign an approved informed consent and authorization 

Intervention

  • Pembrolizumab (Keytruda)
  • Quality of Life questionnaires

Patients will be followed every 6 months until 5 years from start of study, then every year until 10 years from start of study.

For more information, visit the ClinicalTrials.gov.

Key Participation Requirements
Gender
Female
Age
19 years and older
Marker Status
Must be ER/PR/Her2 Negative (Triple Negative)
Phase
Phase III
Methodist Health System Trial Code
S1418
Related Specialties